|
| Press Releases |
|
 |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, May 10, 2022 |
|
|
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway. more info >> |
|
|
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin. more info >> |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Implementation of Measures to Enhance Our Corporate Value in Connection with Toyota Industries Corporation
Jun 3, 2025 19:54 JST
|
|
|
Toyota Group to Accelerate Collaboration Towards Transforming into a Mobility Company Through Privatization of Toyota Industries Corporation
Jun 3, 2025 19:16 JST
|
|
|
Fujitsu accelerates digital transformation of financial institutions with newly systematized business strategy
Jun 3, 2025 18:46 JST
|
|
|
Fintech Forward Set to Return to Bahrain and Gather the Most Influential Leaders in Finance at its Third Edition in October 2025
Jun 3, 2025 17:45 HKT/SGT
|
|
|
Traditional Chinese Medicine Consumption Shows Promising Outlook, with Neautus's Market Leadership Becoming Increasingly Evident
Jun 3, 2025 16:56 HKT/SGT
|
|
|
Shiv Khera's New Book "Live While You're Alive" Launched in Singapore
Jun 3, 2025 15:00 HKT/SGT
|
|
|
transport logistic and HLPFI partner to launch global project cargo platform
Jun 3, 2025 14:04 HKT/SGT
|
|
|
20 Start-ups Showcase at Hong Kong Tech Pavilion in VivaTech 2025
Jun 3, 2025 11:57 HKT/SGT
|
|
|
Anime Tokyo Station Launches Official YouTube Channel
Jun 3, 2025 11:00 JST
|
|
|
Luxren Capital Introduces a New Era in Mobile Trading: Secure, Regulated, and Always at Users' Fingertips 
Jun 3, 2025 05:00 HKT/SGT
|
|
|
IFEX Capital Introduces Its Latest Version of a Groundbreaking Trading Platform Connecting Traders Globally
Jun 2, 2025 22:00 HKT/SGT
|
|
|
NEXX Signs Joint Memorandums of Understanding (MoU) with Milaha and KEC
Jun 2, 2025 19:06 HKT/SGT
|
|
|
New Habitat for Humanity report shows housing improvements in informal settlements promotes health outcomes of women
Jun 2, 2025 19:00 HKT/SGT
|
|
|
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
Jun 2, 2025 17:56 JST
|
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Jun 2, 2025 17:46 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
